Hormonal Therapy in Prostate Cancer

Hormonal Therapy in Prostate Cancer

Improving Clinical Outcomes in Metastatic and Non-Metastatic Disease

Not a member of My prIME? Join now for instant access.

Not an official event of the 2018 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2018 Genitourinary Cancers Symposium.

Meeting Overview

Enhance your understanding of emerging trends and recent clinical trial data on hormonal therapy for prostate cancer.

A variety of topics will be presented, including current and emerging treatment options for castration-resistant prostate cancer, the use of newer hormonal therapies in hormone-sensitive disease and non-metastatic prostate cancer, and safety concerns associated with these newer agents.

Date and Location

Friday, February 9, 2018
7.00 PM – 9.00 PM

Franciscan Ballroom
Park Central Hotel, San Francisco
50 Third Street
San Francisco, California 94103



Friday, February 9, 2018 | 7.00 PM – 9.00 PM



San Francisco, California, United States



1.5 AMA PRA Category 1 Credits™

7.00 PM Registration and dinner
7.30 PM Welcome and introduction
Tomasz Beer, MD, FACP
7.35 PM Endocrine options for castration-resistant prostate cancer (CRPC)
Joaquim Bellmunt, MD, PhD
7.55 PM Developments in treating hormone-sensitive disease: Progress at last
Axel Heidenreich, MD
8.15 PM Focus on safety issues of newer hormonal therapies
Celestia S. Higano, MD, FACP
8.30 PM Looking to the future: Panel discussion
Tomasz Beer, MD, FACP, and all faculty
8.40 PM Ask the experts: Audience Q&A
Tomasz Beer, MD, FACP, and all faculty
8.55 PM prIME Points™
Tomasz Beer, MD, FACP
8.40 PM Adjourn


  • Tomasz Beer, MD, FACP Oregon Health & Sciences University
    Portland, Oregon, United States
  • Faculty

  • Joaquim Bellmunt, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Axel Heidenreich, MD, PhDUniversitätsklinikum Köln
    Cologne, Germany
  • Celestia S. Higano, MD, FACPUniversity of Washington
    Seattle, Washington, United States

This educational activity is specifically designed to meet the needs of medical oncologists, urologists, and other healthcare professionals involved in the treatment of patients with prostate cancer.

After successful completion of this educational activity, participants should be able to:

  • Analyze clinical trial data on the efficacy and safety of current and emerging antagonists and inhibitors of androgen-receptor signaling in the treatment of nonmetastatic and hormone-sensitive metastatic prostate cancer
  • Implement treatment strategies for metastatic prostate cancer that sequence these newer endocrine options earlier in the clinical course of prostate cancer
  • Describe optimal approaches to manage treatment-related adverse events associated with hormonal therapeutic options for prostate cancer that can help maintain quality of life and adherence to treatment

This educational activity is supported by an independent grant from Astellas and Medivation, Inc. a Pfizer company.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.